Peer-Reviewed Publication
Ann Oncol2026June 5, 2026Journal Article
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.
C T A Parker1, H-C Huang2, E Grist1, L Mendes1, R Yamashita2, D Croucher2, A Sachdeva3, L Murphy4, V Y T Liu2, S Santos Vidal1, T Todorovic2, S Lall1, M Goncalves1, S Thakali1, A Wingate1, L Zakka1, D Wetterskog1, K Nowakowska1, C L Amos4, , D M Berney5, P T Tran6, D E Spratt7, M R Sydes4, L C Brown4, S G Zhao8, P Nguyen9, N W Clarke3, C J Sweeney10, E L Stewart2, M K B Parmar4, A Esteva2, N D James11, G Attard12
1Cancer Institute, University College London; London, UK.
2Artera Inc.; Los Altos, California, USA.
3Departments of Surgery and Urology, The Christie and Salford Royal Hospitals; Manchester, UK; Genitourinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
4MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London; London, UK.
5Barts Cancer Institute, Queen Mary University of London; London, UK.
6The University of Texas MD Anderson Cancer Center; Houston, TX, USA.
7UH Seidman Cancer Center, Case Western Reserve University; Cleveland, OH, USA.
8Department of Human Oncology, University of Wisconsin; Madison, WI, USA.
9Mass General Brigham Department of Radiation Oncology/Harvard Medical School; Boston, MA, USA.
10The University of Adelaide South Australian immunoGENomics Cancer Institute (SAiGENCI); Adelaide, Australia.
11Royal Marsden NHS Foundation Trust and Institute of Cancer Research; London, UK.
12Cancer Institute, University College London; London, UK; University College London Hospitals; London, UK. Electronic address: g.attard@ucl.ac.uk.
Abstract
BACKGROUND: Long-term androgen deprivation therapy (LT-ADT) with radiotherapy is standard-of-care for high-risk localized prostate cancer, with abiraterone added for clinically very high-risk disease. Given the toxicity and cost of abiraterone, a predictive biomarker to refine patient selection is needed. We evaluated a digital pathology multimodal artificial intelligence (MMAI) model, previously…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans